Pyridine N-n-alkylation of S(-)-nicotine (NIC) affords N-nalkylnicotinium analogs, previously shown to competitively inhibit [ 3 H]NIC binding and interact with a 4 b 2* nicotinic receptors (nAChRs). The present study determined the ability of the analogs to inhibit NIC-evoked 86 Rb + effl ux from rat thalamic synaptosomes to assess functional interaction with a 4 b 2* nAChRs. In a concentration-dependent manner, NIC evoked 86 Rb + effl ux (EC 50 = 170 nmol/L). Analoginduced inhibition of NIC-evoked 86 Rb + effl ux varied over a ~450-fold range. Analogs with long n -alkyl chain lengths (C 9 -C 12 ) inhibited effl ux in the low nmol/L range (IC 50 = 9-20 nmol/L), similar to dihydro-b -erythroidine (IC 50 = 19 nmol/L). Compounds with shorter n -alkyl chain lengths (C 1 -C 8 ) produced inhibition in the low m mol/L range (IC 50 = 3-12 m mol/L). C 10 and C 12 analogs completely inhibited NIC-evoked effl ux, whereas C 1-9 analogs produced maximal inhibition of only 10% to 60%. While the C 10 analog Nn -decylnicotinium iodide (NDNI) did not produce signifi cant inhibition of NIC-evoked dopamine release in previously reported studies, NDNI possesses high affi nity for [ 3 H]NIC binding sites (K i = 90 nmol/L) and is a potent and effi cacious inhibitor of NIC-evoked 86 Rb + effl ux as demonstrated in the current studies. Thus, NDNI is a competitive, selective antagonist at a 4 b 2* nAChRs.
INTRODUCTION
Activation of neuronal nicotinic receptors (nAChR) results in the transient opening of its ligand-gated ion channel, permitting Ca 2+ , Na + , and K + fl ux, followed by local depolarization of the plasma membrane. 1 The a 4 b 2* nAChR is the predominant heteromeric nAChR subtype in brain, and high affi nity S-(-) 5 , 6 and demonstrate essentially eliminated dihydro-b -erythroidine-sensitive and -resistant 86 Rb + effl ux from thalamus and cerebral cortex. 7 , 8 The 86 Rb + effl ux assay monitors K + fl ux through nAChR channels and characterizes functional interactions with the high affi nity [ 3 H]NIC binding site in native brain tissue preparations (ie, a 4 b 2* nAChRs 7 , 9-11 ) and in cell lines. 12 , 13 86 Rb + effl ux is used also to measure the function of other nAChR receptor subtypes when various subunit combinations are expressed in cell lines. [14] [15] [16] [17] [18] Nicotinic agonist potency in the 86 Rb + effl ux assay using native rodent preparations is highly correlated with affi nity for [ 3 H]NIC binding sites, but not with affi nity for a -[ 125 I]bungarotoxin binding. 9 Surprisingly, inhibition of NIC-evoked 86 Rb + effl ux by a small number of nAChR antagonists was not correlated with affi nity for [ 3 H]NIC binding sites. 9 However, only a limited number of structurally-unrelated nAChR antagonists were investigated in the latter study, likely precluding the establishment of a structure-activity relationship.
Pyridine N-n -alkylation of NIC has afforded a series of N-nalkylnicotinium analogs with carbon chains of C 1 -C 12 . [19] [20] [21] [22] [23] As a result of N -n -alkylation, NIC is converted from a potent agonist into a series of novel compounds with potent and subtype-selective nAChR antagonist properties. The C 8 analog N-n-octylnicotinium iodide (NONI) has been identifi ed as a potent selective inhibitor of nAChR subtypes mediating NIC-evoked [ 3 H]dopamine ([ 3 H]DA) overfl ow from superfused rat striatal slices. 22 NONI almost completely inhibited NIC-evoked [ 3 H]DA overfl ow (Imax = 90%). Of importance, NONI did not exhibit high affi nity for [ 3 H]NIC binding sites, indicative of nAChR subtype selectivity. 23 In contrast, the C 10 analog N-n-decylnicotinium iodide (NDNI) exhibited high affi nity for [ 3 H]NIC binding sites but did not inhibit NIC-evoked [ 3 H]DA overfl ow, again indicative of nAChR subtype selectivity. 22 , 23 In both [ 3 H]DA release and [ 3 H]NIC binding assays, inhibitory potency of the analog series was correlated with n -alkyl chain length (ie, potency increased with increasing n -alkyl chain length). Thus, these results indicate that NDNI selectively interacts with the a 4 b 2* nAChR subtype, that NONI is a selective antagonist at nAChR subtypes mediating NIC-evoked DA release, and that nAChR subtypes primarily mediating NIC-evoked DA release from rat striatal slices is not of a 4 b 2* composition. Inhibition of [ 3 H]NIC binding does not determine whether these N-n -alkylnicotinium analogs act as nAChR agonists or antagonists at high affi nity [ 3 H]NIC binding sites. The purpose of the current study was to evaluate the functional interaction of this series of N-n -alkylnicotinium analogs at the a 4 b 2* nAChR subtype using 86 Rb + effl ux from rat striatal synaptosomes. Initially, the time-and concentrationdependence of the response to NIC in the 86 Rb + effl ux assay was investigated. Subsequently, analog-induced 86 Rb + effl ux (intrinsic activity, agonist response) and ability to inhibit NIC-evoked 86 Rb + effl ux (antagonist activity) were determined and compared with that produced by dihydro-berythroidine (DH b E), a classical competitive nAChR antagonist.
MATERIALS AND METHODS
NIC, DH b E, and N -[2-hydroxyethyl]-piperizine-N ' -[2-ethanesulfonic acid] (HEPES) were purchased from Sigma/ RBI (Natick, MA). a -D-Glucose was purchased from Aldrich Chemical Co (Milwaukee, WI). 86 Rubidium chloride (initial specifi c activity ~100-400 Ci/moL) was obtained from PerkinElmer Life Sciences (Boston, MA). The remaining chemicals contained in the superfusion buffer were obtained from Fisher Scientifi c (Pittsburgh, PA). N-Methylnicotinium iodide (NMNI), N-n -propylnicotinium iodide (NPNI), N-n-butylnicotinium iodide (NnBNI), and NONI were prepared as described by Crooks et al. 19 N -Ethylnicotinium iodide (NENI), N-n-hexylnicotinium iodide (NHxNI), N-n-heptylnicotinium iodide (NHpNI), N-n-nonylnicotinium iodide (NNNI), NDNI, and N-n-dodecylnicotinium iodide (NDDNI) were prepared from NIC and the appropriate n -alkyl iodide using the general procedure described by Xu et al. 24 All synthesized compounds were fully characterized by elemental analysis and determined to be free from NIC using spectroscopic ( 1 H-and 13 C-nuclear magnetic resonance, and fast atom bombardment mass spectroscopy), thin layer chromatographic (silica gel), and combustion analysis procedures. Structures of the N-nalkylnicotinium analogs are provided in Figure 1 .
Male Sprague-Dawley rats (200-250 g) were obtained from Harlan Laboratories (Indianapolis, IN) and were housed 2 per cage with free access to food and water in the Division of Laboratory Animal Resources at the College of Pharmacy, University of Kentucky. Experimental protocols involving animals were in accordance with the 1996 National Institutes of Health (NIH) Guide for the Care and Use of Laboratory Animals and were approved by the Institutional Animal Care and Use Committee at the University of Kentucky. For each experiment, thalamus from an individual rat was dissected and gently homogenized (20 up and down strokes of a Tefl on-glass homogenizer) in 1 mL icecold buffer (320 mM sucrose and 5 mM HEPES, pH 7.5). Subsequently, homogenate was centrifuged (3000 g for 10 minutes at 4°C) using a Beckman centrifuge (model GS-15R, Beckman Coulter, Fullerton, CA), and the supernatant was centrifuged (12 000 g for 20 minutes at 4°C). The resulting pellet was resuspended in a volume of uptake buffer (140 mM NaCl, 1.5 mM KCl, 2 mM CaCl 2 , 1 mM MgSO 4 , 25 mM HEPES, 20 mM glucose; pH 7.5) providing a protein concentration of ~40 m g/25 m L synaptosomal suspension. Thalamic synaptosomes were used owing to the relatively high density of a 4 b 2* nAChRs in this tissue. 10 Synaptosomal aliquots (25 m L) were incubated with 10 m L of 86 RbCl (~0.5 mM total 86 Rb + concentration) in uptake buffer for 30 minutes at ~25°C. 86 Rb + uptake was terminated by fi ltration onto 6-mm diameter type gas chromatography (GC) glass fi ber fi lters (Micro Filtration Systems, Dublin, CA) under gentle vacuum (~0.2 atm), followed by 3 washes with 0.5 mL uptake buffer at 25°C. The 6-mm diameter glass fi ber fi lters containing the 86 Rb + -preloaded synaptosomes were placed on 13-mm glass fi ber fi lters (type A/E) positioned on plastic Swinney holders (Gelman Life Sciences Inc, Ann Arbor, MI) that were mounted on a polypropylene platform to begin superfusion. Synaptosomes were superfused (1.0 mL/min) with buffer containing 135 mM NaCl, 1.5 mM KCl, 2 mM CaCl 2 , 1 mM MgSO 4 , 5 mM CsCl, 50 nmol/L tetrodotoxin (TTX), 25 mM HEPES, 20 mM a -D-glucose, 1.0 g/L bovine serum albumin (BSA) (pH 7.5, ~25°C). CsCl and TTX were included in the buffer to block voltage-gated K + and Na + channels, respectively, and to reduce the rate of basal fractional 86 Rb + outfl ow, thereby optimizing the signal-to-noise ratio.
To identify the concentration of NIC to be used in experiments determining N-n-alkylnicotinium analog-induced inhibition of NIC-evoked response, an initial series of experiments was performed in which the concentrationdependence of NIC to evoke 86 Rb + effl ux from preloaded thalamic synaptosomes was determined. Sample collection began after 8 minutes of superfusion. Superfusate fractions were collected in 20-second intervals (0.3 mL vol) into 4-mL scintillation vials using a Retriever II fraction collector (ISCO Inc, Lexana, KS). To determine the basal fractional 86 Rb + outfl ow, samples were collected for a 5-minute period. After collection of 15 basal samples, synaptosomes from an individual rat were superfused in the absence or presence of 1 of 6 concentrations of NIC (30 nmol/L to 10 m mol/L) for 3 minutes to determine the concentration dependence of NIC-evoked 86 Rb + effl ux. Superfusion continued for an additional 3-minute period with buffer in the absence of NIC. Radioactivity in superfusate and tissue samples was determined by adding 3.7 mL water to each sample, followed by measurement of Cerenkov radiation using a scintillation counter (model B1600 TR, Packard Bioscience Co, Meriden, CT).
The ability of N-n-alkylnicotinium analogs (1 nmol/L to 100 m mol/L) to evoke 86 Rb + effl ux and to inhibit NICevoked 86 Rb + effl ux was determined and compared with DH b E (1 nmol/L to 100 m mol/L). Sample collection began after 8 minutes of superfusion. To determine basal fractional 86 Rb + outfl ow, samples were collected for a 2-minute period. After collection of 6 basal samples, synaptosomes from an individual rat were superfused in the absence or presence of 1 of 6 concentrations of analog or DH b E for 3 minutes, to determine the intrinsic activity of the compounds to evoke 86 Rb + effl ux. Subsequently, NIC (1 m mol/L) was added to buffer and superfusion was continued for an additional 3 minutes, followed by superfusion for 3 minutes with buffer in the absence of analog or NIC. To maximize the ability to detect analog-induced inhibition of NIC-evoked 86 Rb + effl ux, the concentration (1 m mol/L) of NIC chosen for these experiments was at the top of the linear portion of the NIC concentration-response curve. Each aliquot of thalamic synaptosomes from an individual rat was exposed to only one concentration of analog or DH b E. In each experiment, one synaptosomal aliquot was exposed to NIC (1 m mol/L) in the absence of analog or DH b E (NIC control), and one synaptosomal aliquot was superfused in the absence of either NIC or analog (buffer control) to determine basal 86 Rb + effl ux during the entire course of the experiment. Thus, a repeatedmeasures design was used; the concentration response for analog-induced intrinsic and inhibitory activity was determined using synaptosomes from each rat.
To determine the baseline cpm for fractional 86 Rb + outfl ow across the entire superfusion period, an exponential decay curve was fi t to the data (cpm) preceding drug exposure and during the recovery period (Sigma Plot 2000, SPSS Inc, Chicago, IL). Subsequently, time-course data for analog-, DH b E-, and NIC-evoked increases in 86 Rb + effl ux were converted to fractional 86 Rb + effl ux by the equation (sample cpm -baseline cpm) ÷ baseline cpm. Fractional increases in 86 Rb + effl ux were summed to obtain total 86 Rb + effl ux during the entire period of superfusion with respective compound. To reduce variability within and between experiments, total 86 Rb + effl ux was normalized to 86 Rb + content in the corresponding synaptosomal aliquot and then multiplied by 100, to obtain total 86 Rb + effl ux as a percentage of tissue 86 Rb + content.
The initial series of experiments determining the concentration-dependence of NIC to increase fractional 86 Rb + effl ux was analyzed by analysis of variance (ANOVA), and the concentration-response curves were modeled to obtain pharmacological parameters. The time course of the concentration-dependent effect of NIC to increase fractional 86 Rb + effl ux from thalamic synaptosomes was analyzed also by 2-way repeated measures ANOVA with NIC concentration and collection fraction as within-subject factors. Subsequently, Dunnett ' s post hoc analyses determined the concentrations of NIC that increased fractional 86 Rb + effl ux above the mean basal 86 Rb + outfl ow at specifi c collection fractions. Furthermore, the maximal increase in fractional 86 Rb + effl ux at each concentration of NIC was analyzed by 1-way ANOVA. Dunnett ' s analysis was used to determine signifi cant differences between maximal NIC-evoked outfl ow and maximal fractional outfl ow in the buffer control condition. Tukey ' s test was used to determine differences in maximal effect produced by the various concentrations of NIC. NIC-evoked total 86 Rb + effl ux from thalamic synaptosomes was expressed as a function of log NIC concentration. Variable slope sigmoid concentration-response curves were fi t to data using nonlinear least squares regression. The sigmoid curve was defi ned by the equation
, where Y is the total 86 Rb + effl ux expressed as percentage tissue content; X is the log NIC concentration; log EC 50 is the log NIC concentration that increased 86 Rb + effl ux by 50%; n is the Hill coeffi cient; and Bt and Tp are the minimum and maximum total 86 Rb + effl ux, respectively ( Bt and Tp were allowed to vary to obtain a unique curve fi t).
To determine the ability of the N-n -alkylnicotinium analogs to evoke total 86 Rb + effl ux (intrinsic activity) and to begin to assess structure-activity relationships, a 2-way ANOVA was performed with n -alkyl chain length as a between-groups factor and analog concentration as a within-subject factor. Subsequently, 1-way ANOVAs were performed for each analog and for DH b E to determine concentrations that signifi cantly increased total 86 Rb + effl ux. Dunnett ' s post hoc analyses determined analog or DH b E concentrations increasing total 86 Rb + effl ux relative to buffer control.
To determine the ability of the N-n -alkylnicotinium analogs to inhibit NIC-evoked total 86 Rb + effl ux, data were expressed as NIC-evoked 86 Rb + effl ux as a function of the logarithm of analog concentration. Concentration-response curves were modeled using a variable slope sigmoid fi t to the data. Inhibition curves were fi t using nonlinear least squares regression, using the equation
, where Y is the total 86 Rb + effl ux expressed as percentage tissue content; X is the log NIC concentration; log IC 50 is the log analog or DH b E concentration, which decreased 86 Rb + effl ux by 50%; n is the pseudo-Hill coefficient; and Bt and Tp are the minimum and maximum total 86 Rb + effl ux, respectively. All data parameters were derived from computer-aided curve fi tting, and statistical analyses were performed using the commercially available software packages SigmaPlot (Version 6.0, Jandel Scientifi c, Corte Madera, CA), PRISM (Version 3.0, GraphPad Software Inc, San Diego, CA), and SPSS standard (Version 9.0, SPSS Inc, Chicago, IL). The SigmaPlot program used embedded macros for nonlinear regression fi tting of effl ux data (cpm). Unless noted otherwise, the best-fi t curve was defi ned as that which minimized the absolute squared distance (Y 2 ) from each data point to the curve.
RESULTS

NIC-evoked 86 Rb + Effl ux
The time course of the concentration-response for NIC to evoke fractional 86 Rb + effl ux from 86 Rb + preloaded rat thalamic synaptosomes is illustrated in Figure 2 . Fractional 86 Rb + effl ux from thalamic synaptosomes was stable during the 440-second superfusion period with buffer alone (collection samples 1-22, Figure 2 , top panel). Two-way repeated measures ANOVA of basal effl ux prior to NIC exposure revealed that both the main effects and the chamber x superfusate sample interaction were not signifi cant ( P > .05). Figure 2 (top panel). Tissue 86 Rb + content (cpm) was determined at the end of the collection period. 86 Rb + effl ux from synaptosomes exposed to buffer (in the absence of NIC) constituted the control (CON) condition in each experiment. Each data point represents the mean 6 SEM of 4 to 6 independent observations. thereafter, reaching levels of control effl ux after 100 to 200 seconds, depending upon the NIC concentration. For subsequent analysis of the concentration-effect of NIC, data from collection samples 19 to 36 were analyzed by 2-way repeated measures ANOVA. A signifi cant interaction of NIC concentration x collection sample was found ( F 102,510 = 6.16; P < .0001). Of note, when the superfusion buffer was changed, a small but signifi cant increase in 86 Rb + effl ux was observed in the chamber superfused with buffer only, which was likely due to mechanical manipulation of the system. Moreover, data from the fi rst sample immediately following exposure to the various concentrations of NIC showed that fractional 86 Rb + effl ux increased in a concentration-dependent manner. A signifi cant effect of NIC concentration on maximal 86 Rb + effl ux was found ( F 6,41 = 14.1; P < .0001). Post hoc analysis revealed that the lowest NIC concentration (30 nmol/L) did not increase 86 Rb + effl ux compared with control, whereas higher concentrations of NIC increased the response. A plateau in the NIC concentration response was observed with 3 m mol/L; and 1 m mol/L NIC produced a reliable increase in fractional 86 Rb + effl ux across the duration of drug exposure.
Analysis of NIC-evoked total 86 Rb + effl ux from thalamic synaptosomes cumulated across the duration of superfusion with NIC revealed a sigmoid concentration-response curve (Hill coeffi cient = 0.84 ± 0.28, n H ± SE; Figure 2 
N-n -Alkylnicotinium Analog-evoked Total 86 Rb + Effl ux
The ability of N-n -alkylnicotinium analogs to evoke total 86 Rb + effl ux from thalamic synaptosomes (intrinsic activity) was determined by cumulating the amount of 86 Rb + effl ux during the 200-second exposure to each concentration of analog to the superfusion buffer ( Table 1 ) . At the highest concentration (100 m mol/L) examined, NDNI (C 10 analog) and NDDNI (C 12 analog) evoked signifi cant 86 Rb + effl ux, which did not return to basal levels, precluding calculation of total 86 Rb + effl ux (data not included in Table 1 ). Repeated-measures, 2-way ANOVA revealed a signifi cant compound x concentration interaction ( F 48,96 = 1.72; P < .05). Separate 1-way repeated-measures ANOVAs for each N-n-alkylnicotinium analog and for DH b E were performed. A signifi cant main effect of concentration was found for NMNI (C 1 : F 6,30 = 4.78; P < .005), NENI (C 2 : F 6,32 = 3.74; P < .01), NnBNI (C 4 : F 6,32 = 3.84; P < .01), NHxNI (C 6 : F 6,31 = 3.55; P < .05), NNNI (C 9 : F 6,34 = 4.01; P < .01), NDNI (C 10 : F 6,34 = 2.68; P < .05), and DH b E ( F 6,30 = 7.89; P < .0001); however, orderly concentration-dependent relationships were not observed.
N-n -Alkylnicotinium Analog-induced Inhibition of NIC-evoked 86 Rb + Effl ux
For each experiment assessing analog-induced inhibition of NIC (1 m mol/L) response, one synaptosomal aliquot served as a within-subject NIC control. The IC 50 values were either in the nmol/L or in the μmol/L range (ie, a 3-order of magnitude difference in inhibition potency was observed). NnBNI, N-n-butylnicotinium iodide; NHxNI, N-n-hexylnicotinium iodide; NHpNI, N-n-heptylnicotinium iodide; NONI, N-n-octylnicotinium iodide; NNNI, N-n-nonylnicotinium iodide; NDNI, N-n-decylnicotinium iodide; NDDNI, N-n-dodecylnicotinium iodide; ND, not determined; and NA, not applicable. Data represent the mean Ϯ SEM of the mean of n = 4 to 6 independent observations at each concentration of analog or DH b E. NDNI and NDDNI evoked 86 Rb + effl ux from thalamic synaptosomes, showing intrinsic activity at 100 μmol/L; however, since effl ux did not return to basal levels following analog exposure, total 86 Rb + effl ux values could not be calculated, therefore these data are not included in the Table. E927
Inhibition profi les for C 9-12 analogs and DH b E, exhibiting IC 50 values in the nmol/L range, are shown in Figure 3 (top panel). Inhibition profi les for C 1-8 analogs, exhibiting IC 50 values in the m mol/L range, are shown in Figure 3 (bottom panel). The C 10 analog (NDNI), C 12 analog (NDDNI), and DH b E were equipotent and completely inhibited the effect of NIC ( Figure 3 , top panel) . The C 9 analog (NNNI) produced a maximal 60% inhibition of the NIC response at a concentration of 100 nmol/L. Rb + effl ux 6 SEM as a percentage of tissue 86 Rb + content and split into 2 sets based on affi nity range. Inhibition profi les for analogs (C 9-12 ) and DH b E, which inhibit NIC-evoked 86 Rb + effl ux in the low nanomolar range (see Table 2 ), are shown in the top panel; inhibition profi les for analogs (C 1-8 ), which inhibit NIC-evoked 86 Rb + effl ux in the low micromolar range (see Table 2 ), are shown in the bottom panel. Numbers in parentheses in the legends indicate n -alkyl chain length. Each data point represents the mean (6 SEM) of 3 to 5 independent observations from individual rats. The present study demonstrates that N-n -Alkylnicotinium analogs inhibit NIC-evoked 86 Rb + effl ux, demonstrating functional antagonism at a 4 b 2* nAChRs. N-n -alkylnicotinium analogs produced inhibition of NIC-evoked 86 Rb + effl ux and could be divided into high (C [9] [10] [11] [12] ) and low (C 1-8 ) potency classes. Several possible mechanisms could explain the existence of these 2 distinct potency classes: (1) differential interaction of the analogs with more than one nAChR subtype, (2) interaction with multiple a 4 b 2* isoforms, (3) interaction with alternative subunit stoichiometries of the a 4 b 2* subtype, and (4) interaction with distinct affi nity states of the a 4 b 2* nAChR. Coexpression of the a 5 subunit with a 4 and b 2 subunits in cultured cell systems (eg, a 4 a 5 b 2) has been shown to alter agonist effi cacy and potency, as well as receptor desensitization and open channel properties. 28 Furthermore, splice variants of the rat a 4 subunit C-terminus have been reported. 29 , 30 More recently, a single nucleotide polymorphism in the a 4 subunit gene has been associated with altered 86 Rb + effl ux in mouse. 31 , 32 Alternatively, altered subunit stoichiometries (eg, expression of a 4 and b 2 subunits in either a 1:9 a : b ratio or a 9:1 ratio) also have been reported to result in nAChRs differentially sensitive to agonist stimulation and antagonist inhibition. 33 Furthermore, differential co-expression of a 4 and b 2 subunit gene transcripts has been observed in various rat brain regions. 34 On the other hand, distinct affi nity states of the a 4 b 2* subtype are consistent with those described by theoretical models. [35] [36] [37] Analogs containing N -n -alkyl substituents of C 9-12 chain length (NNNI, NDNI, and NDDNI) may interact preferentially with a high affi nity state of a 4 b 2* nAChRs, while C 1-8 analogs may interact with a low affi nity state. Thus, the high and low potency classes of these analogs may refl ect the presence of more than one isoform, stoichiometry, or state of the a 4 b 2* nAChR in rat thalamus.
Of interest, these structurally related N-n -alkylnicotinium analogs potently (IC 50 = 0. 
CONCLUSIONS
The present study further extends the characterization of the nAChR properties of a novel class of brain-bioavailable N-nalkylnicotinium ligands. The results indicate that C 9-12 N-nalkyl analogs are potent functional inhibitors at a 4 b 2* nAChRs.
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The C 10 analog NDNI exhibits potent and selective antagonism at a 4 b 2* nAChR and may provide a useful tool for elucidating the physiological function of this nAChR subtype, as well as providing a novel therapeutic approach to treating disorders associated with alterations in nAChR function.
